| Literature DB >> 24949485 |
Doron Boltin1, Ibrahim Zvidi1, Adam Steinmetz2, Hanna Bernstine2, David Groshar2, Yuval Nardi3, Mona Boaz4, Yaron Niv1, Ram Dickman1.
Abstract
BACKGROUND: Gastroparesis is a heterogeneous disorder most often idiopathic, diabetic, or postsurgical in nature. The demographic and clinical predictors of gastroparesis in Israeli patients are poorly defined.Entities:
Mesh:
Year: 2014 PMID: 24949485 PMCID: PMC4037617 DOI: 10.1155/2014/294032
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Patient characteristics.
|
| |
|---|---|
|
| 193 (100) |
| Age y (mean (SD)) | 60.15 (15.61) |
| Male | 76 (39.38) |
|
| 44 (22.80) |
| Smoking | 20 (10.36) |
| Symptoms | |
| Dysphagia | 25 (12.95) |
| Early satiety | 133 (68.91) |
| Vomiting | 71 (36.79) |
| Bloating | 142 (73.58) |
| Diabetes | 79 (40.93) |
| HBA1C§ % (mean (SD)) | 7.70 (1.87) |
| Neuropathy | 34 (43.04) |
| Retinopathy | 41 (51.90) |
| nephropathy | 25 (31.65) |
| Antidiabetic medication¥ | 76 (96.20) |
| Cardiovascular disease | 139 (72.02) |
| Hypertension | 105 (54.40) |
| Dyslipidemia | 132 (68.39) |
| Ischemic heart disease | 43 (22.28) |
| Peripheral vascular disease | 22 (11.40) |
| Scleroderma | 14 (7.25) |
| Gastroesophageal surgery | 18 (9.32) |
| GERD | 94 (48.70) |
| Medications | |
| Oral hypoglycemic | 51 (26.42) |
| Insulin | 34 (17.62) |
| Antiaggregant¶ | 96 (49.74) |
| Antihypertensive | 108 (55.96) |
| Antisecretory# | 147 (76.17) |
| Narcotic | 7 (3.63) |
| Metoclopramide /domperidone | 57 (29.53) |
§Data missing for 5 subjects; ¥insulin, oral hypoglycemic agents, or both; ¶aspirin, clopidogrel, or both; #H2-receptor antagonist (10 cases), proton pump inhibitor (126 cases), or both (11 cases).
Independent predictors of prolonged gastric emptying.
| OR (95% CI) |
| |||
|---|---|---|---|---|
| Group 3/group 1* | Group 2/group 1* | Group 3/group 2* | ||
| Dysphagia | 3.44 (1.10, 10.78) | 2.09 (1.05, 4.16) | 1.65 (0.49, 6.00) | 0.021 |
| Vomiting | 4.06 (1.14, 14.51) | 2.54 (1.20, 5.35) | 1.60 (0.41, 6.00) | 0.008 |
| Diabetes | 0.83 (0.35, 2.01) | 0.42 (0.22, 0.81) | 1.98 (0.77, 5.00) | 0.032 |
| Proton pump inhibitor | 0.94 (0.38, 2.35) | 2.43 (1.15, 5.13) | 0.39 (0.14, 1.00) | 0.046 |
| H2 antagonist | 2.34 (0.78, 7.02) | 0.35 (0.09, 1.28) | 6.74 (1.54, 30.00) | 0.002 |
| Metoclopramide | 2.43 (0.93, 6.32) | 3.29 (1.64, 6.60) | 0.74 (0.29, 2.00) | 0.002 |
*Group 1: T 1/2 0–99 minutes; group 2: T 1/2 100–299 minutes; group 3: T 1/2 ≥ 300 minutes.
Figure 1Prevalence of upper gastrointestinal tract symptoms in subjects undergoing gastric emptying scintigraphy.
Figure 2Gastric emptying in idiopathic and diabetic subjects. (a) Percentage of previously healthy (idiopathic) subjects. (b) Percentage of diabetic subjects with normal (<100 mins), mildly delayed (100–299 mins), and grossly delayed gastric emptying (≥300 mins).
Clinical associations of gastroparesis.
| Group 1¥ | Group 2 | Group 3 | Total | |
|---|---|---|---|---|
| Idiopathic | 46 (49.5) | 36 (38.7) | 11 (11.8) | 93 (100) |
| Male | 20 (43.5) | 13 (36.1) | 3 (27.3) | 36 (38.7) |
| Age mean (SD) | 59.20 (17.7) | 57 (19.5) | 54.64 (17.8) | 57.81 (18.3) |
|
| 11 (23.9) | 8 (22.2) | 3 (27.3) | 22 (23.7) |
| Secondary§
| 55 (55.0) | 31 (31.0) | 14 (14.0) | 100 (100) |
| Male | 25 (45.5) | 11 (35.5) | 4 (28.6) | 40 (40.0) |
| Age mean (SD) | 63.45 (11.3) | 59.29 (13.9) | 64.57 (12.1) | 62.32 (12.3)* |
|
| 11 (20.0) | 5 (16.2) | 6 (42.9) | 22 (22.0) |
| Diabetes | 49 (62.0) | 13 (16.5) | 17 (21.5) | 79 (100) |
| Male | 20 (40.8) | 5 (38.5) | 6 (35.3) | 31 (39.2) |
| Age mean (SD) | 63.7 (11.2) | 64.2 (9.6) | 64.1 (11.2) | 63.8 (10.8)* |
|
| 10 (20.4) | 1 (7.7) | 6 (35.3) | 17 (21.5) |
*P < 0.05 (compared to idiopathic group).
§Diabetes mellitus, scleroderma, and prior surgery.
Group 1: T 1/2 0–99 min; group 2: T 1/2 100–299 min; group 3: T 1/2 ≥ 300 min.